Skip to main content
SpringerLink
Log in

Pharmacological Activity of Antisense Oligonucleotides in Animal Models of Disease

  • Chapter
Antisense Research and Application

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 131))

Abstract

Over the last 20 years, antisense oligonucleotide approaches have proven to be extremely valuable methods for characterizing the function of specific gene products and for addressing and optimizing antisense mechanisms of action. Numerous reviews have been published describing some of the accomplishments in this area, some of which are cited here (Crooke 1992;Bennett et al 1995;Field and Goodchild 1995;Crooke and Bennett 1996). However, it has only been within the last 5–7 years that antisense technology has progressed such that the therapeutic value of these compounds can be evaluated in animal models of human disease. Over this period, reports demonstrating pharmacological activities of antisense oligonucleotides in animal models have accelerated at an impressive rate in a number of therapeutic areas, most commonly cancer, restenosis, and inflammation. In many of these studies, the pharmacological activity reported for the antisense oligonucleotides was very controlled such that it is difficult to ascribe a mechanism of action other than antisense. Many of these studies have been included in prior reviews of the antisense field (Bennett et al 1995;Field and Goodchild 1995;Crooke and Bennett 1996).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 429.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 549.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 549.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abe J-I, Zhou W, Taguchi J-I, Takuwa N, Miki K, Okazaki H, Kurokawa K, Kumada M, Takuwa Y (1994) Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery. Biochem Biophys Res Comm 198(1):16–24

    Article  PubMed  CAS  Google Scholar 

  • Aiello LP, Pierce EA, Robinson GS, Ferrara N, Smith LEH (1995a) Vascular endothelial growth factor (VEGF) antagonists inhibit retinal neovascularization. Diabetes 44(1):53

    Google Scholar 

  • Aiello LP, Pierce EA, Robinson GS, Ferrara N, Smith LEH (1995b) Vascular endothelial growth factor (VEGF) antagonists inhibit retinal neovascularization. Diabetes 44(1):53

    Google Scholar 

  • Autieri MV, Yue T-L, Ferstein GZ, Ohlstein E (1995) Antisense oligonucleotides to the P65 subunit of NF-kB inhibit human vascular smooth muscle cell adherence and proliferation and prevent neointima formation in rat carotid arteries. Biochem Biophys Res Commun 213(3):827–836

    Article  PubMed  CAS  Google Scholar 

  • Bennett MR, Schwartz SM (1995) Antisense therapy for angioplasty restenosis. Circulation 92(7):1981–1993

    Article  PubMed  CAS  Google Scholar 

  • Bennett CF, Chiang M-Y, Wilson-Lingardo L, Wyatt JR (1994) Sequence specific inhibition of human type II phospholipase A2 enzyme activity by phosphorothioate oligonucleotides. Nucleic Acids Res 22(15): 3202–3209

    Article  PubMed  CAS  Google Scholar 

  • Bennett CF, Dean N, Ecker DJ, Monia BP (1995) Pharmacology of antisense therapeutic agents: cancer and inflammation. In: Agrawal S, Totowa N (eds) Methods in molecular medicine: antisense therapeutic. Humana, Clifton

    Google Scholar 

  • Bereck KH, Kirk KA, Nagahama S, Oparil S (1987) Sympathetic function in spontaneously hypertensive rats after chronic administration of captopril. Am J Physiol 252: H796–H806

    Google Scholar 

  • Burgess TL, Fisher EF, Ross SL, Bready JV, Qian Y-X, Bayewitch LA, Cohen AM, Herrera CJ, Hu SS-F, Kramer TB, Lott FD, Martin FH, Pierce GF, Simonet L, Farrell CL (1995) The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci U S A 92:4051–4055

    Article  PubMed  CAS  Google Scholar 

  • Chaikof EL, Caban R, Yan G-N, Rao GN, Runge MS (1995) Growth-related responses in arterial smooth muscle cells are arrested by thrombin receptor antisense sequences. J Biol Chem 270:7481–7486

    Google Scholar 

  • Chiou HC, Tangco MV, Levine SM, Robertson D, Kormis K, Wu CH, Wu GY (1994) Enhanced resistance to nuclease degradation of nucleic acids complexed to asialoglycoprotein-polylysine carriers. Nucleic Acids Res 22(24):5439–5446

    Article  PubMed  CAS  Google Scholar 

  • Choi B-M, Kwak H-J, Jun C-D, Park S-D, Kim K-Y, Kim H-R, Chung H-T (1996) Control of scarring adult wounds using antisense transforming growth factor-PI_ oligodeoxynucleotides. Immunol Cell Biol 74:144–150

    Article  PubMed  CAS  Google Scholar 

  • Christofidou-Solomidou M, Albelda SM, Bennett CF, Murphy GF (1997) Experimental production and modulation of human cytotoxic dermatitis in human-murine chimeras. Am J Pathol 150(2):631–639

    PubMed  CAS  Google Scholar 

  • Cioffi CL, Garay M, Johnston JF, McGraw K, Boggs RT, Hreniuk D, Monia BP (1997) Selective inhibition of A-raf and C-raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: role of A-raf and C-raf in serum-induced proliferation. Mol Pharmacol 51:383–389

    PubMed  CAS  Google Scholar 

  • Crooke ST (1992) Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol 32:329–76

    Article  PubMed  CAS  Google Scholar 

  • Crooke ST, Bennett CF (1996) Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol. Toxicol 36:107–29

    Article  CAS  Google Scholar 

  • Dean NM, McKay R. (1994) Inhibition of protein kinase C-a expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc Natl Acad Sci 91:11762–11766

    Article  PubMed  CAS  Google Scholar 

  • Delafontaine P, Meng XP, Ku L, Du J (1995) Regulation of vascular smooth muscle cell insulin-like growth factor 1 receptors by phosphorothioate oligonucleotides. Effects on cell growth and evidence that sense targeting at the ATG site increases receptor expression. J Biol Chem 270:14383–14388

    Article  PubMed  CAS  Google Scholar 

  • Desjardins JP, Iversen PL (1995) Inhibition of rat cytochrome P450 3A2 by an antisense phosphorothioate oligodeoxynucleotide in vivo. J Pharmacol Exp Ther 275:1608–1613

    PubMed  CAS  Google Scholar 

  • Desjardins J, Mata J, Brown T, Graham D, Zon G, Iversen P (1995) Cholesterylconjugated phosphorothioate oligodeoxynucleotides modulate CYP2B1 expression in vivo. J Drug Target 2:477–485

    Article  PubMed  CAS  Google Scholar 

  • Ecker DJ, Vickers TA, Hanecak R, Driver F, Anderson K (1993) Rational screening of oligonucleotide combinatorial libraries for drug discovery. Nucleic Acids Res 21(8):1853–1856

    Article  PubMed  CAS  Google Scholar 

  • Epstein SE, Speir E, Finkel T (1993) Do antisense approaches to the problem of restenosis make sense? Circulation 88:1351–1353

    Article  PubMed  CAS  Google Scholar 

  • Field AK, Goodchild J (1995) Antisense oligonucleotides: rational drug design for genetic pharmacology. Exp Opin Invest Drugs 4(9):799–821

    Article  CAS  Google Scholar 

  • Gillardon F, Eschenfelder C, Uhlmann E, Hartschuh W, Zimmermann M (1994) Differential regulation of c-fos,fosB, c jun, junB, bcl-2 and bax expression in rat skin following single or chronic ultraviolet irradiation and in vivo modulation by antisense oligodeoxynucleotide superfusion. Oncogene 9:3219–3225

    PubMed  CAS  Google Scholar 

  • Gillardon F, Moll I, Uhlmann E (1995) Inhibition of c-fos expression in the UV-irradiated epidermis by topical application of antisense oligodeoxynucleotides suppresses activation of proliferating cell nuclear antigen. Carcinogenesis 16(8):1853–1856

    Article  PubMed  CAS  Google Scholar 

  • Gyurko R, Wielbo D, Phillips MI (1993) Antisense inhibition of AT, receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin. Regul Pept 49:167–174

    Article  PubMed  CAS  Google Scholar 

  • Lu X, Fischman AJ, Jyawook SL, Hendricks K, Tompkins RG, Yarmush ML (1994) Antisense DNA delivery in vivo: liver targeting by receptor-mediated uptake J Nucl Med 35:269–275

    CAS  Google Scholar 

  • Mann MJ, Gibbons GH, Kernoff RS, Diet FP, Tsao PS, Cooke JP, Kaneda Y, Dzau VJ (1995) Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci U S A 92:4502–4506

    Article  PubMed  CAS  Google Scholar 

  • Merrilees MJ, Scott L (1994) Antisense S-oligonucleotide against transforming growth factor-ß, inhibits proteoglycan synthesis in arterial wall. J Vasc Res 31:322–329

    Article  PubMed  CAS  Google Scholar 

  • Monia BP, Johnston JF, Sasmor H, Cummins LL (1996). Nuclease resistance and antisense activity of modified oligonucleotides targeted to ha-ras. J Biol Chem 271(24):14533–14540

    Article  PubMed  CAS  Google Scholar 

  • Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ (1993) Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci U S A 90:8474–8478

    Article  PubMed  CAS  Google Scholar 

  • Morishita R, Gibbons GH, Ellison KE, Nakajima M, Leyen HVD, Zhang L, Kaneda Y, Ogihara T, Dzau VJ (1994a) Intimal hyperplasia after vascular injury is inhibited by antisense cdk2 kinase oligonucleotides. J Clin Invest 93:1458–1464

    Article  CAS  Google Scholar 

  • Morishita R, Gibbons GH, Kaneda Y, Ogihara T, Dzau VJ (1994b) Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B, and CDC2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene 149:13–19

    Article  CAS  Google Scholar 

  • Nestle FO, Mitra RS, Bennett CF, Chan H, Nickoloff BJ (1994) Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes. J Invest Dermatol 103(4):569–575

    Article  PubMed  CAS  Google Scholar 

  • Noiri E, Peresieni T, Miller F, Goligorsky MS (1996) In vivo targeting of inducible NO synthase with oligodeoxynucleotides protects rat kidney against ischemia. J Clin Invest 97(10):2377–2383

    Article  PubMed  CAS  Google Scholar 

  • Nyce JW, Metzger WJ (1997) DNA antisense therapy for asthma in an animal model. Nature 385(20):721

    Article  PubMed  CAS  Google Scholar 

  • Phillips MI, Kimura BC (1988) Brain angiotensin in the developing spontaneously hypertensive rat. J Hypertens 6:607–612

    Article  PubMed  CAS  Google Scholar 

  • Pickering G, Weir I, Jekanowski J, Isner JM (1992) Inhibition of proliferation of human vascular smooth muscle cells using antisense oligodeoxynucleotides to PCNA. J Am Coll Cardiol 19:165 (abstr)

    Google Scholar 

  • Pickering JG, Isner JM, Ford CM, Weir L, Lazarovits A, Rocnik EF, Chow LH (1996) Processing of chimeric antisense oligonucleotides by human vascular smooth muscle cells and human atherosclerotic plaque. Circulation 93(4):772–780

    Article  PubMed  CAS  Google Scholar 

  • Robinson GS, Pierce EA, Rook SL, Foley E, Webb R, Smith LEH (1996) Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci U S A 93:4851–4856

    Article  PubMed  CAS  Google Scholar 

  • Schlessinger J (1994) SH2/SH8 signaling proteins. Curr Opin Genet Dev 4:25–30

    Article  PubMed  CAS  Google Scholar 

  • Schumacher C, Sharif H, Haston W, Wennogle L, Monia BP, Cioffi CL (1997) Exposure of human vascular smooth muscle cells to raf-1 antisense oligodeoxynucleotides: cellular responses and pharmacodynamic implications. Mol Pharmacol (in press)

    Google Scholar 

  • Shi Y, Hutchinson HG, Hall DJ, Zalewaski A (1993) Downregulation of c-myc expression by antisense oligonucleotides inhibits proliferation of human smooth muscle cells. Circulation 88:1190–1195

    Article  PubMed  CAS  Google Scholar 

  • Shi Y, Fard A, Galeo A, Hutchinson HG, Vermani P, Dodge GR, Hall DJ, Shaheen F, Zalewski A (1994) Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation 90:944–951

    Article  PubMed  CAS  Google Scholar 

  • Simons M, Rosenberg RD (1992) Antisense nonmuscle myosin heavy chain and c-myb oligonucleotides suppress smooth muscle cell proliferation in vitro. Circ Res 70(4):835–843

    Article  PubMed  CAS  Google Scholar 

  • Simons M, Edelman ER, DeKeyser JL, Langer R, Rosenberg RD (1992) Antisense cmyb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 359:67–70

    Article  PubMed  CAS  Google Scholar 

  • Simons M, Edelman ER, Rosenberg RD (1994) Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model. J Clin Invest 93:2351–2356

    Article  PubMed  CAS  Google Scholar 

  • Smith LEH, Pierce EA, Aiello LP, Foley E, Sullivan R, Rook SL, Robinson GS (1995) Inhibition of proliferative retinopathy using antisense phosphorothioate oligonucleotides against vascular endothelial growth factor (VEGF/VPF). Invest Ophthalmol Vis Sci 36(4):871

    Google Scholar 

  • Speir E, Epstein SE (1992) Inhibition of smooth muscle cell proliferation by an antisense oligodeoxynucleotide targeting the messenger RNA encoding proliferating cell nuclear antigen. Circulation 86:588–547

    Article  Google Scholar 

  • Sugano M, Makino N (1996) Changes in plasma lipoprotein cholesterol levels by antisense oligodeoxynucleotides against cholesteryl ester transfer protein in cholesterol-fed rabbits. J Biol Chem 271(32):19080–19083

    Article  PubMed  CAS  Google Scholar 

  • Wielbo D, Sernia C, Gyurko R, Phillips MI (1995) Antisense inhibition of hypertension in the spontaneously hypertensive rat. Hypertension 25(3):314–319

    Article  PubMed  CAS  Google Scholar 

  • Wyatt JR, Vickers TA, Roberson JL, Buckheit RW Jr, Klimkait T, DeBaets E, Davis PW, Rayner B, Imbach JL, Ecker DJ (1994) Combinatorially selected guanosinequartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc Natl Acad Sci U S A 91(4):1356–1360

    Article  PubMed  CAS  Google Scholar 

  • Yaswen P, Stampfer MR, Ghosh K, Cohen JS (1993) Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells. Antisense Res Dev 3:67–77

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. B. P. Monia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. M. Dean
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. ISIS Pharmaceuticals, Inc., Carlsbad Research Center, 2292 Faraday Avenue, Carlsbad, CA, 92008, USA

    Stanley T. Crooke M.D., Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Monia, B.P., Dean, N.M. (1998). Pharmacological Activity of Antisense Oligonucleotides in Animal Models of Disease. In: Crooke, S.T. (eds) Antisense Research and Application. Handbook of Experimental Pharmacology, vol 131. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-58785-6_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-58785-6_14

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-63730-8

  • Online ISBN: 978-3-642-58785-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation